Jun 5, 2019
VS partner and hemp practice chair Shawn Hauser made a formal presentation to the U.S. Food and Drug Administration at its historic public hearing regarding the regulation of products containing cannabis or cannabis-derived compounds. Her testimony, which she provided on behalf of the Cannabis Trade Federation, was highlighted by multiple news outlets.
Marijuana Moment reported:
Advocates, industry representatives, regulators, health professionals and marijuana legalization opponents stood up before the Food and Drug Administration (FDA) on Friday to share their perspectives on how to best approach regulating the cannabis compound CBD.
Shawn Hauser, a hemp and cannabinoid attorney with the law firm Vicente Sederberg LLP, represented the Cannabis Trade Federation at the hearing. “The appropriate regulation of products containing lawful cannabinoids already exists, and that data arising out of the state-regulated regime supports such regulation,” she said.
But “whether right or wrong, the current situation has created a vacuum. It opens the door to bad actors,” which ought to inform the FDA’s next steps.
“Cannabis products can be safely regulated under the existing dietary supplement framework and where products are intended for non-medicinal purposes, it is appropriate to regulate them as such,” she said. “The years of data from these state regulatory regimes are an important source of data for the agency to consider in determining the regulatory pathway. We stand ready to advance to the next level as a partner with FDA in effective federal regulation of cannabinoid products.”
The Cannabis Trade Federation has published Shawn's full testimony online.